TileBio Ltd

TileBio Ltd, based in the UK, specializes in artificial intelligence solutions for pathology, focusing on automating the interpretation of histopathology images to improve diagnostic accuracy and efficiency. TileBio Ltd, founded in 2025, is headquartered in Glasgow, UK. The company develops advanced AI technologies for pathology, enhancing diagnostic processes. It raised GBP 1.

6 million in Seed funding on March 2, 2026, led by Twin Path Ventures, with support from Scottish Enterprise and the University of Glasgow. This funding is part of their initial investment strategy, marking their first deal. TileBio specializes in advanced artificial intelligence pathology solutions, centered on the development of large-scale foundation models that interpret histopathology images without the need for human labeling. Their core offering is an AI-learned visual language of tissue, designed to automate the understanding and interpretation of complex pathological data.

This innovative approach enhances clinical diagnostics, biomarker discovery, and target development by allowing healthcare professionals to identify subtle patterns in tissue biology that are often imperceptible to the human eye. TileBio's technology is aimed at clinical laboratories, pharmaceutical companies, and research institutions globally, with a specific focus on addressing the challenges posed by the shortage of pathologists and the limitations of traditional, human-labeled datasets. Their products are targeted toward markets in North America, Europe, and Asia, where the demand for sophisticated diagnostic tools is rapidly increasing. TileBio generates revenue through strategic partnerships and direct sales of its AI pathology solutions to healthcare providers and research institutions.

The business transactions typically involve subscription-based models for access to their proprietary AI tools and large language model services, allowing clients to integrate these technologies into their existing workflows. Clients include hospitals, clinical laboratories, and pharmaceutical firms that leverage the company’s unique offerings to improve diagnostic accuracy and accelerate research initiatives. The pricing structures are designed to accommodate various client needs, fostering scalable engagement that aligns with the extensive applications of their technology in diagnostics and drug discovery. As TileBio continues to expand its client base and enhance its product offerings, it aims to solidify its position as a leader in AI-driven pathology solutions.

TileBio plans to utilize its most recent funding of GBP 1. 6 million to expand its technical team, scale the training of its pathology foundation model, and establish early clinical, life sciences, and pharmaceutical partnerships. The company is focused on launching innovative new products aimed at improving diagnostic capabilities within the healthcare sector. Specifically, they intend to expand their market presence in North America, Europe, and Asia by 2027, aligning their growth strategy with the increasing demand for advanced diagnostic tools.